SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Panel Rejects FDA and Genentech (South SF)'s (JOBS) Xolair Asthma Drug for Children

November 19, 2009 | 
1 min read

Bookmark and Share

Reuters -- Roche and Novartis’s asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.

Regulatory
Genentech, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Donald Trump behind a podium
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former CytoDyn Officials Found Guilty of Securities Fraud
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac